0
Abstract: Poster Presentations |

THE THERAPEUTIC EFFECT OF TREATMENT WITH FORMOTEROL PLUS TIOTROPIUM WAS GREATER THAN THE EFFECT OF TREATMENT WITH TIOTROPIUM ALONE IN COPD: FINDINGS FROM A 12-WEEK, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, TRIAL FREE TO VIEW

Donald Tashkin, MD*; Santosh Varghese, MD
Author and Funding Information

David Geffen School of Medicine, Los Angeles, CA


Chest


Chest. 2007;132(4_MeetingAbstracts):529a. doi:10.1378/chest.132.4_MeetingAbstracts.529a
Text Size: A A A
Published online

Abstract

PURPOSE: The β2-adrenergic receptor agonists and anticholinergics are two distinct classes of bronchodilators that have different therapeutic effects in patients with chronic obstructive pulmonary disease (COPD). We report results from a clinical trial designed to investigate whether the therapeutic effect associated with treatment with formoterol (FORM) plus tiotropium (TIO) was greater than the effect of treatment with TIO alone in patients with COPD.

METHODS: 12-week, randomized, placebo-controlled, double-blind, parallel-group, multicenter study in COPD patients aged ≥40 years who were current or ex-smokers. Patients received FORM 12μg BID and TIO 18μg QD or TIO 18μg QD and placebo. The primary efficacy endpoint was the change from baseline in the normalized area under the curve (AUC) for FEV1 measured 0 to 4 hours postmorning dose (FEV1 AUC 0–4h) at the last visit. Secondary efficacy endpoints included comparisons of trough effects on FEV1 and FVC (average of values 10 and 30 minutes predose) and onset of effects on FEV1 following the first dose.

RESULTS: FORM+TIO (n=116) significantly increased the normalized FEV1 AUC 0-4h compared with TIO (n=124) at all time points postbaseline, with mean treatment differences that reached clinical significance (>100mL change). Mean treatment differences (95% CI) at weeks 4, 8, and 12, and endpoint were 150mL (90, 220), 170mL (100, 230), 180mL (120, 240), and 170mL (120, 230), respectively (all P<0.001). At endpoint, increases from baseline in trough FEV1 and FVC were significantly greater with FORM+TIO (n=121) than with TIO (n=129), with mean treatment differences of 80mL and 160mL, respectively (both P=0.004). The increase in FEV1 5 minutes postdose was significantly greater with FORM+TIO than with TIO (180mL vs 40mL, respectively; P<0.001). Both treatments were similarly well tolerated.

CONCLUSION: The therapeutic effect of treatment with FORM+TIO was greater than the effect of treatment with TIO alone in COPD patients. Significant differences between treatments were observed as early as 5 minutes postdose (the first scheduled measurement).

CLINICAL IMPLICATIONS: The effect of FORM+TIO was greater than the effect of TIO alone in COPD patients.

DISCLOSURE: Donald Tashkin, No Product/Research Disclosure Information; Grant monies (from industry related sources) Dr. Tashkin has received industry-sponsored grants from Schering-Plough; Consultant fee, speaker bureau, advisory committee, etc. Dr. Tashkin has received honoraria for advisory boards and speaking engagements from Schering-Plough.

Wednesday, October 24, 2007

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543